Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06852768
PHASE1/PHASE2

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Sponsor: Regenerative Ocular Immunobiologics LLC

View on ClinicalTrials.gov

Summary

A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGHVD)

Official title: A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1

Start Date

2025-01-10

Completion Date

2026-12

Last Updated

2026-02-03

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

d-MAPPS

Based on randomization d-MAPPS, will be self-administered, 2 drops into each eye four times a day (QID) a day for ninety (90) days.

BIOLOGICAL

Placebo

Based on randomization, Placebo, will be self-administered, 2 drops into each eye four times (QID) a day for ninety (90) days.

OTHER

PI and Patient Masked

Both the PI and the participant are masked on the drug administered.

Locations (5)

Beverly Hills Institute of Ophthalmology

Beverly Hills, California, United States

Beach Eye Medical Group

Huntington Beach, California, United States

Regenerative Ocular Immunobiologics, LLC.

Palm Harbor, Florida, United States

Glenn Eye Center

Lexington, Kentucky, United States

Eyewell, LLC.

Boston, Massachusetts, United States